Aeglea BioTherapeutics, Inc./$SYRE
1D1W1MYTD1Y5YMAX
Capital at risk
About Aeglea BioTherapeutics, Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
- Ticker
- $SYRE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 125
- Headquarters
- Waltham, United States
- Website
- www.spyre.com
SYRE Metrics
BasicAdvanced
$8.2B
-
-$2.01
3.03
-
Price and volume
Market cap
$8.2B
Beta
3.03
52-week high
$110.18
52-week low
$15.86
Average daily volume
1.3M
Financial strength
Current ratio
18.53
Quick ratio
18.232
Profitability
Management effectiveness
Return on assets (TTM)
-19.81%
Return on equity (TTM)
-22.98%
Valuation
Price to book
8.6
Price to tangible book (TTM)
8.6
Price to free cash flow (TTM)
-50.125
Free cash flow yield (TTM)
-2.00%
Free cash flow per share (TTM)
-1.859
Growth
Earnings per share change (TTM)
-30.11%
3-year earnings per share growth (CAGR)
-69.64%
10-year earnings per share growth (CAGR)
-33.95%
What the Analysts think about SYRE
Analyst ratings (Buy, Hold, Sell) for Aeglea BioTherapeutics, Inc. stock.
Analyst projections of the future price of Aeglea BioTherapeutics, Inc. stock.
Bulls say / Bears say
Spyre has now achieved clinical proof-of-concept for all three UC components: SPY001, SPY002 and SPY003 each met its primary RHI endpoint. The results give the company a credible base for testing its combination strategy. (GlobeNewswire, Spyre Therapeutics)
The company is testing three pairwise antibody combinations in SKYLINE Part B, using long-acting molecules designed for infrequent subcutaneous maintenance dosing. If combining complementary immune pathways improves disease control without sacrificing tolerability, Spyre could offer both stronger efficacy and greater convenience than single-agent treatment. (GlobeNewswire, Spyre Therapeutics)
Spyre held $1.145 billion in cash, cash equivalents and marketable securities at the end of June, with management projecting funding into the second half of 2029. That gives it time to reach several readouts, including rheumatic-disease data in late 2026 and the key combination data in 2027, without an immediate funding crisis. (Spyre Therapeutics)
The central combination thesis is still unproven. SKYLINE Part B is only enrolling now, and topline induction data are not expected until 2027, so there is no clinical evidence yet that the combinations outperform the individual antibodies. (GlobeNewswire, Spyre Therapeutics)
Spyre has no product revenue and continues to fund a loss-making clinical pipeline; its six-month 2026 net loss was about $105 million. The April equity raise strengthened the balance sheet but increased the share count, and the company says it will need further financing before development and commercialisation are complete. (StockTitan, Spyre Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
SYRE Financial Performance
Revenues and expenses
SYRE Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing SYRE
AllUSDGBPEUR
Fund name | Fund size | $SYRE weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.53% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.53% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.23% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.23% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.